Colonoscopy Screening for Ulcerative Colitis: Cost-Effectiveness

By Staff Writer

March 18, 2024

Introduction

Ulcerative colitis (UC), a chronic disease impacting the large intestine. It is becoming increasingly prevalent, not just globally, but also specifically in Saudi Arabia. Individuals with long-standing UC are at a higher risk of developing colorectal cancer (CRC), a serious complication associated with inflammatory bowel disease (IBD). With the potential risk of CRC in UC patients being 1.7 times higher than the general population, it is crucial to establish effective and cost-effective screening methods.

The Controversy Surrounding Surveillance Colonoscopy

Surveillance colonoscopy, a method used to detect dysplasia in UC patients, has been shown to be effective in reducing CRC rates. Yet, there is ongoing debate about the cost-effectiveness of this screening method. While some studies suggest that surveillance can increase life expectancy, others argue that it may not always be cost-effective. Especially in the Middle Eastern context, this is observed.

The Saudi Scenario

A recent study focused on the cost-consequence analysis of annual colonoscopy surveillance among high-risk UC patients in Saudi Arabia. The findings revealed that this practice results in higher costs but lower rates of dysplasia detection. They found that each 1% reduction in dysplasia rates was associated with an incremental cost of USD 740.125. If we assume that a 50% decrease in high grade dysplasia rates will lead to at least one extra quality-adjusted life year (QALY), then the USD 37,006.25 (50 times USD 740.125) is more than the recently released cost-effectiveness threshold for Saudi Arabia, which is USD 20,183 per QALY.

Limitations of Annual Screening

The cost-effectiveness of annual colonoscopy screening among high-risk UC patients in the Middle Eastern population is yet to be reported. A systematic review found that all CRC screening techniques were more cost-effective than no screening at different cost-effectiveness criteria. Although a colonoscopy every 10 years was cost-effective, most trials reported greater costs than no screening, and ICERs exceeded USD 20,000 in several cases. Furthermore, the discomfort associated with colonoscopy and the lack of endoscopic capacity in Saudi Arabia make annual colonoscopy screening not just cost-ineffective but inconvenient to patients and the healthcare system.

Potential AI Intervention

The potential of artificial intelligence (AI) in screening CRC is worth investigating. A study examining the adoption of AI in colonoscopy for CRC screening resulted in a significant reduction in CRC incidence (8.4 %) and mortality (6.9 %), suggesting a promising direction for future research.

The Role of Albumin Levels

The study also revealed that patients who had higher albumin levels were less likely to have dysplasia compared to those with hypoalbuminemia. This finding is consistent with another study that examined the use of albumin as a prognostic marker for ulcerative colitis.

Concluding Thoughts

Adherence to annual colonoscopy for CRC screening has resulted in higher rates of dysplasia detection among long-standing UC patients. However, this comes with a significant incremental cost. Based on recent findings, performing colonoscopy for CRC screening on an annual basis is likely to be inefficient. Thus, longitudinal prospective cohort studies should examine the cost-effectiveness of various CRC screening strategies, including 5-year and 10-year colonoscopies.

Reference url

Recent Posts

U.S. withdraws from WHO
     

U.S. Withdraws from WHO: Impact on Global Health Security and Relations

🚨 *What does the U.S. withdrawing from the WHO mean for global health?*
President Trump’s executive order to begin the withdrawal process raises serious concerns about the future of global health security. From financial disparities to a shift in international partnerships, the implications could reshape our collective ability to combat pandemics and health crises.

Dive into our article to understand the potential impacts on health outcomes and the quest for new alliances.

#SyenzaNews #globalhealth #healthcarepolicy

semaglutide NAION risk
    

Semaglutide NAION Risk: EMA Review Initiated Amid Conflicting Evidence

🔍 Is semaglutide linked to vision loss?

The European Medicines Agency’s PRAC is currently reviewing the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with semaglutide-containing medicines, including popular treatments like Ozempic and Wegovy. With recent studies yielding conflicting evidence, this review is crucial for patient safety and the future of these therapies.

Read the full article to understand the implications and what this could mean for healthcare providers and patients alike!

#SyenzaNews #Pharmaceuticals #HealthcarePolicy

cervical cancer screening
        

Cost-Effective Cervical Cancer Screening Strategies for Women with HIV in KwaZulu-Natal

💡 *Are single-visit cervical cancer screenings the key to better health outcomes in high HIV prevalence areas?*
A recent study from KwaZulu-Natal, South Africa reveals that repeat single-visit cervical cancer screening using HPV DNA testing is not only the most effective but also the most cost-effective approach for women living with HIV. This aligns with WHO recommendations for comprehensive cervical cancer elimination strategies.

Explore the insights and implications of this vital research that could transform cervical cancer prevention in resource-limited settings.

#SyenzaNews #HealthEconomics #oncology #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.